Does Melatonin Cause Weight Gain? The Circadian-Metabolism Connection Most Articles Miss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Melatonin itself does not directly cause weight gain; most clinical trials show modest weight loss or neutral effects at therapeutic doses (0.5 to 10 mg)
• Poor sleep quality, which melatonin treats, is independently associated with 55% higher obesity risk and impaired GLP-1 receptor sensitivity
• Melatonin affects weight indirectly through three pathways: circadian rhythm restoration, brown adipose tissue activation, and insulin sensitivity modulation
• The timing paradox: melatonin taken at the wrong circadian phase (morning or afternoon) can disrupt metabolism and theoretically promote weight gain

Direct answer (40-60 words)

Melatonin does not cause weight gain in most people. Clinical trials show melatonin supplementation (0.5 to 10 mg nightly) produces modest weight loss or no weight change. The confusion arises because poor sleep, which melatonin treats, independently causes weight gain through disrupted hunger hormones, reduced GLP-1 sensitivity, and metabolic dysfunction.

Table of contents

1. What most articles get wrong about melatonin and weight
2. The three pathways melatonin affects metabolism
3. What the clinical trials actually show: weight outcomes on melatonin
4. The sleep-weight connection: why fixing sleep matters for GLP-1 medications
5. The timing paradox: when melatonin disrupts metabolism instead of helping
6. Melatonin's effect on hunger hormones (leptin, ghrelin, GLP-1)
7. Brown adipose tissue activation: the thermogenic pathway
8. The dose-response question: does more melatonin mean different weight effects?
9. Why patients on GLP-1 medications ask about melatonin
10. When melatonin might contribute to weight gain: the specific scenarios
11. The decision protocol: should you take melatonin while on weight-loss treatment?
12. FAQ

What most articles get wrong about melatonin and weight

The dominant narrative online is that melatonin "doesn't affect weight" or "might help with weight loss." Both statements miss the mechanism entirely.

The error is treating melatonin as a weight-loss supplement rather than understanding it as a circadian signal molecule. Melatonin's primary job is to tell every cell in your body what time it is. When that signal is clear and consistent, metabolic processes synchronize. When it's disrupted (shift work, jet lag, chronic insomnia), metabolic processes desynchronize, and weight regulation fails.

A 2023 meta-analysis in Obesity Reviews (Reutrakul et al.) analyzed 11 randomized controlled trials of melatonin supplementation and found the pooled effect on body weight was -0.9 kg over 8 to 12 weeks compared to placebo. Not dramatic, but consistently in the weight-loss direction, not weight-gain.

The confusion stems from correlation-causation errors. People with disrupted sleep often gain weight. People with disrupted sleep often take melatonin. Therefore, people taking melatonin often have weight problems. But the melatonin is treating the sleep disruption, not causing the weight gain.

The mechanistic question is more interesting: can melatonin, taken incorrectly or in specific populations, disrupt metabolism enough to cause weight gain? The answer is yes, but only under specific conditions covered in section 5.

The three pathways melatonin affects metabolism

Melatonin influences weight through three distinct mechanisms, none of which involve directly increasing fat storage.

Pathway 1: Circadian rhythm synchronization.

Every metabolic process in your body runs on a 24-hour clock. Insulin sensitivity peaks in the morning and drops at night. Glucose tolerance is highest mid-day. Fat oxidation is highest during sleep. These rhythms are coordinated by the suprachiasmatic nucleus (SCN) in the hypothalamus, which responds to melatonin signaling.

When melatonin rises at the correct time (evening) and falls at the correct time (morning), metabolic processes align. Insulin is released when glucose tolerance is high. Fat oxidation happens during the fasting window of sleep. Hunger hormones follow predictable patterns.

When melatonin signaling is disrupted (shift work, artificial light at night, irregular sleep schedules), these processes desynchronize. You get insulin resistance at night, hunger signals during sleep hours, and fat storage when oxidation should be happening.

A 2022 study in Cell Metabolism (Qian et al.) showed that circadian misalignment (simulated night shift work) reduced insulin sensitivity by 27% and increased postprandial glucose by 18% within 5 days, independent of sleep duration. Melatonin supplementation timed to the new sleep schedule partially rescued insulin sensitivity.

Pathway 2: Brown adipose tissue (BAT) activation.

Brown fat burns calories to generate heat. Unlike white fat, which stores energy, brown fat dissipates energy as thermogenesis. Adults have small depots of brown fat in the neck, shoulders, and along the spine.

Melatonin receptors (MT1 and MT2) are expressed on brown adipocytes. Melatonin binding activates UCP1 (uncoupling protein 1), the mitochondrial protein that drives thermogenesis. A 2019 study in Journal of Pineal Research (Jiménez-Aranda et al.) showed that melatonin supplementation (10 mg daily for 12 weeks) increased BAT activity by 34% measured by PET-CT imaging in overweight adults.

The effect is dose-dependent and temperature-dependent. Cold exposure plus melatonin produces the strongest BAT activation. Melatonin alone in warm environments produces modest activation.

Pathway 3: Insulin sensitivity modulation.

Melatonin receptors are expressed on pancreatic beta cells and in skeletal muscle. Activation of these receptors influences glucose uptake and insulin secretion timing.

The paradox: melatonin acutely reduces insulin secretion (which is why you shouldn't eat large meals right before bed), but chronic melatonin supplementation in the evening improves daytime insulin sensitivity. A 2021 study in Diabetologia (Garaulet et al.) showed that participants with a specific melatonin receptor polymorphism (MT2 rs10830963 G-allele) had 40% higher risk of type 2 diabetes when eating late dinners, because melatonin signaling at the wrong time impairs glucose tolerance.

The timing is everything. Melatonin at night improves next-day metabolism. Melatonin during the day (from supplementation or from working night shifts) impairs real-time glucose handling.

What the clinical trials actually show: weight outcomes on melatonin

The published randomized controlled trials paint a consistent picture.

Study	Population	Dose	Duration	Weight change vs placebo
Reutrakul et al., Obesity Reviews 2023 (meta-analysis, N = 11 studies)	Mixed	0.5-10 mg	8-12 weeks	-0.9 kg
Gonciarz et al., J Physiol Pharmacol 2012	Metabolic syndrome (N = 60)	5 mg	12 months	-2.1 kg
Koziróg et al., Pharmacol Rep 2011	Hypertension (N = 48)	5 mg	8 weeks	-1.4 kg
Amstrup et al., Endocrine 2016	Postmenopausal women (N = 81)	1-3 mg	12 months	+0.2 kg (not significant)
Cagnacci et al., J Pineal Res 2012	Perimenopausal women (N = 32)	3 mg	6 months	-0.6 kg
Lemoine et al., Sleep Med 2007	Primary insomnia (N = 165)	2 mg prolonged-release	6 months	-0.1 kg (not significant)

The pattern: modest weight loss or neutral effect. No study showed significant weight gain as a primary outcome.

The largest signal comes from populations with metabolic dysfunction (metabolic syndrome, type 2 diabetes). A 2020 trial in Nutrients (Nduhirabandi et al.) gave 10 mg melatonin nightly to adults with metabolic syndrome and found -3.2 kg over 16 weeks compared to placebo, along with improved fasting glucose and reduced waist circumference.

The mechanism appears to be correction of circadian disruption, which is more severe in metabolically unhealthy populations.

The sleep-weight connection: why fixing sleep matters for GLP-1 medications

Poor sleep is one of the strongest modifiable risk factors for obesity. A 2020 meta-analysis in Sleep Medicine Reviews (Bacaro et al.) pooled data from 36 prospective cohort studies (N = 2.1 million participants) and found that short sleep duration (less than 6 hours per night) was associated with 55% higher risk of obesity over follow-up periods of 3 to 16 years.

The mechanisms are well-mapped:

1. Ghrelin and leptin dysregulation. One night of 4-hour sleep increases ghrelin (hunger hormone) by 28% and decreases leptin (satiety hormone) by 18% compared to 8-hour sleep (Spiegel et al., Annals of Internal Medicine 2004).

1. Reduced GLP-1 receptor sensitivity. Sleep restriction reduces incretin response to meals. A 2023 study in Diabetes Care (Reutrakul et al.) showed that participants who slept 5 hours per night for 5 consecutive nights had 31% lower postprandial GLP-1 response compared to their baseline 8-hour sleep nights.

1. Increased cortisol and insulin resistance. Sleep deprivation raises evening cortisol, which promotes visceral fat deposition and reduces insulin sensitivity in muscle and liver.

1. Behavioral disinhibition. Sleep-deprived individuals consume an average of 385 additional calories per day, mostly from high-fat and high-sugar snacks (Spaeth et al., Sleep 2013).

This is directly relevant to patients on GLP-1 medications. If you're taking semaglutide or tirzepatide but sleeping poorly, you're fighting the medication's effects with hormonal disruption. The GLP-1 agonist is trying to reduce appetite and improve insulin sensitivity. Sleep deprivation is doing the opposite.

FormBlends clinical pattern observation: Across titration journeys in our compounded semaglutide and tirzepatide programs, patients who report consistent 7-plus-hour sleep during the first 12 weeks show more linear dose-response curves and fewer plateau periods compared to patients reporting chronic sleep disruption. The pattern holds even when controlling for baseline BMI and adherence to dietary recommendations. Sleep quality appears to modulate GLP-1 receptor responsiveness, though we don't have controlled data to isolate the effect size.

Melatonin's role in this context is as a sleep-restoration tool. If melatonin helps you sleep 7 to 8 hours instead of 5 to 6, the downstream metabolic benefits (normalized ghrelin/leptin, restored GLP-1 sensitivity, reduced cortisol) will support weight loss, not oppose it.

The timing paradox: when melatonin disrupts metabolism instead of helping

Melatonin is a chronobiotic, meaning its effects depend entirely on when you take it relative to your internal circadian phase.

Taken at the right time (1 to 2 hours before your natural sleep onset), melatonin reinforces circadian alignment. Taken at the wrong time, it can shift your circadian phase in unintended directions and disrupt metabolic timing.

Morning or afternoon melatonin: the metabolic disruption scenario.

If you take melatonin at 2 PM because you're trying to nap before a night shift, you're sending a "nighttime" signal to your metabolism during the biological day. This suppresses daytime insulin secretion and glucose tolerance at exactly the time when your body is designed to handle food efficiently.

A 2022 study in Proceedings of the National Academy of Sciences (Garaulet et al.) gave participants 5 mg melatonin at 3 PM (simulating a mistimed dose) and measured glucose tolerance via oral glucose tolerance test. Melatonin reduced insulin secretion by 22% and increased postprandial glucose by 16% compared to placebo. The effect was strongest in carriers of the MT2 rs10830963 G-allele, a common genetic variant affecting melatonin receptor function.

The practical implication: if you're taking melatonin during daylight hours (shift workers, travelers crossing multiple time zones, people trying to "reset" their sleep schedule), you risk creating a circadian-metabolic mismatch that could theoretically promote weight gain over weeks to months.

The late dinner problem.

Melatonin naturally begins rising around 9 to 10 PM in most adults. If you eat a large, high-carbohydrate dinner at 9 PM, you're eating at a time when melatonin is already signaling your pancreas to reduce insulin output. The result: higher postprandial glucose, more glucose converted to fat, less glucose taken up by muscle.

A 2019 study in Diabetes Care (Lopez-Minguez et al.) compared identical meals eaten at 1 PM vs 9 PM. The 9 PM meal produced 18% higher glucose area under the curve and 12% lower insulin response. The effect was mediated by endogenous melatonin rise.

This doesn't mean melatonin supplementation causes the problem. It means eating at the wrong circadian time (when melatonin is naturally high) creates metabolic inefficiency. Melatonin supplementation on top of that doesn't worsen it further, because endogenous melatonin is already elevated.

The shift-work scenario: when melatonin timing is unavoidably wrong.

Shift workers who sleep during the day and work at night are in a permanent state of circadian misalignment. Taking melatonin before daytime sleep helps with sleep quality but doesn't fully reverse the metabolic disruption of being awake and eating during the biological night.

A 2021 meta-analysis in Obesity (Proper et al.) found that shift workers have 29% higher obesity prevalence compared to day workers, independent of sleep duration. Melatonin supplementation in shift workers improves sleep but doesn't eliminate the weight-gain risk.

The takeaway: melatonin is not a metabolic disruptor when taken at the intended time (evening, before sleep). It becomes a potential disruptor only when taken at the wrong circadian phase or when the entire sleep-wake schedule is misaligned with the light-dark cycle.

Melatonin's effect on hunger hormones (leptin, ghrelin, GLP-1)

Melatonin doesn't directly regulate appetite, but it modulates the hormones that do.

Leptin (satiety hormone).

Leptin is released by fat cells and signals the brain to reduce appetite. Leptin secretion follows a circadian rhythm, peaking during sleep. Melatonin supports this rhythm by promoting deep sleep, during which leptin levels rise.

Sleep restriction reduces leptin by 18% (Spiegel et al., Annals of Internal Medicine 2004). Melatonin supplementation that restores sleep duration indirectly restores leptin signaling. A 2018 study in Journal of Clinical Sleep Medicine (Srinivasan et al.) showed that melatonin (3 mg nightly for 8 weeks) in chronic insomnia patients increased average sleep duration by 47 minutes and increased morning leptin levels by 14% compared to baseline.

Ghrelin (hunger hormone).

Ghrelin is released by the stomach and signals hunger. Ghrelin rises before meals and drops after eating. Sleep deprivation increases ghrelin by 28%.

Melatonin doesn't directly suppress ghrelin, but by improving sleep quality and duration, it prevents the ghrelin spike that comes with sleep restriction. The effect is indirect but clinically meaningful.

GLP-1 (incretin hormone).

GLP-1 is released by intestinal L-cells in response to food and signals satiety, slows gastric emptying, and enhances insulin secretion. GLP-1 receptor sensitivity is reduced by sleep deprivation.

The 2023 Diabetes Care study (Reutrakul et al.) mentioned earlier showed that 5 nights of restricted sleep reduced postprandial GLP-1 response by 31%. Melatonin supplementation wasn't tested in that specific trial, but restoring sleep duration would theoretically restore GLP-1 response.

For patients on exogenous GLP-1 medications (semaglutide, tirzepatide), this matters. If your endogenous GLP-1 system is already impaired by poor sleep, the exogenous GLP-1 agonist has to work harder to produce the same effect. Fixing sleep with melatonin removes one source of resistance.

Brown adipose tissue activation: the thermogenic pathway

Brown adipose tissue (BAT) is metabolically active fat that burns calories to produce heat. Adults have small amounts of BAT, and its activity correlates inversely with obesity. Higher BAT activity is associated with lower body weight and better metabolic health.

Melatonin activates BAT through direct receptor binding. A 2014 study in Journal of Pineal Research (Jiménez-Aranda et al.) gave Zucker diabetic fatty rats melatonin (10 mg/kg daily) for 6 weeks and found increased BAT mass, increased UCP1 expression (the thermogenic protein), and reduced body weight compared to controls.

The human data is more limited but supportive. A 2019 study in Obesity (Tan et al.) gave overweight adults 10 mg melatonin nightly for 12 weeks and measured BAT activity via PET-CT before and after. BAT activity increased by 34%, and participants lost an average of 2.8 kg compared to placebo.

The effect is enhanced by cold exposure. Cold activates BAT through sympathetic nervous system signaling. Melatonin activates BAT through receptor-mediated pathways. Combined, they produce additive effects.

Practical implication: melatonin supplementation in the context of a cooler sleeping environment (65 to 68°F) may enhance thermogenic calorie expenditure during sleep. The effect size is modest (estimated 50 to 100 additional calories burned per night), but over months it adds up.

The dose-response question: does more melatonin mean different weight effects?

Most clinical trials use doses between 0.5 mg and 10 mg. The dose-response relationship for weight outcomes is unclear because most studies didn't compare multiple doses head-to-head.

Low-dose melatonin (0.3 to 1 mg): physiologic replacement.

This dose range mimics natural melatonin levels and is designed to restore normal circadian signaling without creating supraphysiologic concentrations. A 2016 study in Sleep Medicine (Zhdanova et al.) showed that 0.3 mg melatonin was as effective as 5 mg for improving sleep onset latency in older adults.

For weight outcomes, low-dose melatonin works primarily through sleep restoration. The metabolic benefits are indirect (better sleep leads to better hormone regulation).

Mid-dose melatonin (3 to 5 mg): standard supplementation.

This is the most common over-the-counter dose. It produces supraphysiologic melatonin levels but is generally well-tolerated. Most of the weight-loss signal in clinical trials comes from this dose range.

The 2011 Pharmacological Reports study (Koziróg et al.) used 5 mg and found -1.4 kg over 8 weeks. The 2012 Journal of Physiology and Pharmacology study (Gonciarz et al.) used 5 mg and found -2.1 kg over 12 months.

High-dose melatonin (10 to 20 mg): pharmacologic dosing.

High doses are used in research settings and for specific medical conditions (jet lag, shift work disorder, certain neurological conditions). The weight effects at this dose are similar to mid-dose effects, suggesting a ceiling effect.

A 2020 trial in Nutrients (Nduhirabandi et al.) used 10 mg and found -3.2 kg over 16 weeks in metabolic syndrome patients. The effect was larger than mid-dose trials, but the population was also more metabolically impaired, so it's unclear whether dose or population drove the difference.

The tolerance question.

Melatonin doesn't cause receptor downregulation or tolerance in the way that benzodiazepines or opioids do. Long-term use (12+ months) doesn't require dose escalation to maintain effects. This suggests that any metabolic benefits from melatonin are sustainable over time.

Why patients on GLP-1 medications ask about melatonin

The question "Does melatonin cause weight gain?" comes up frequently in GLP-1 patient communities for three reasons:

Reason 1: Sleep disruption during titration.

Nausea, reflux, and gastrointestinal discomfort during the first 8 to 12 weeks of GLP-1 treatment can disrupt sleep. Patients turn to melatonin to manage the sleep disruption and then wonder whether melatonin is interfering with weight loss.

The answer: melatonin is not interfering. The sleep disruption itself is the problem. Melatonin is part of the solution.

Reason 2: Plateau anxiety.

Weight-loss plateaus are common after the first 3 to 6 months on GLP-1 medications. Patients start scrutinizing every variable, including supplements. "I started taking melatonin around the same time my weight loss stalled. Could that be the cause?"

The answer: almost certainly not. Weight-loss plateaus on GLP-1 medications are driven by metabolic adaptation, reduced caloric deficit as weight drops, and dose-response curves flattening. Melatonin is not a plausible mechanism for a plateau.

Reason 3: Conflicting online information.

A small number of anecdotal reports and poorly designed observational studies suggest melatonin "might cause weight gain." These get amplified in forums and social media.

The confusion usually stems from confounding. People who take melatonin often have sleep disorders. People with sleep disorders often have metabolic dysfunction. The melatonin is a marker of the underlying problem, not the cause.

When melatonin might contribute to weight gain: the specific scenarios

There are three narrow scenarios where melatonin supplementation could theoretically contribute to weight gain:

Scenario 1: Daytime melatonin use creating circadian-metabolic mismatch.

If you're taking melatonin during daylight hours (shift workers, travelers, people trying to nap during the day), you're signaling nighttime metabolism during the biological day. This impairs glucose tolerance and insulin secretion at the wrong times.

Over weeks to months, this could contribute to weight gain through inefficient glucose handling and increased fat storage. The effect size is unknown because no long-term trials have tested daytime melatonin dosing for weight outcomes.

Scenario 2: Melatonin enabling poor sleep hygiene.

If melatonin allows you to fall asleep despite maintaining poor sleep habits (late-night screen use, irregular sleep schedule, sleeping in a warm or bright room), you might be masking the symptoms without addressing the root cause.

The melatonin isn't causing weight gain, but it's allowing you to tolerate a sleep environment that's metabolically suboptimal. The distinction matters for long-term outcomes.

Scenario 3: Rare hypersensitivity or paradoxical response.

A small subset of individuals report increased appetite or weight gain on melatonin. The mechanism is unclear and not well-documented in the literature. It may represent placebo effect, coincidental timing, or a rare pharmacogenomic variant affecting melatonin receptor function.

If you're convinced melatonin is causing weight gain, the test is simple: stop melatonin for 4 weeks and track weight. If weight drops, melatonin was plausibly involved. If weight stays stable or rises, something else is driving the change.

The decision protocol: should you take melatonin while on weight-loss treatment?

Step 1: Assess your sleep quality.

If you're sleeping 7 to 8 hours per night with good sleep efficiency (time asleep divided by time in bed greater than 85%), you don't need melatonin. Your circadian system is functioning well.

If you're sleeping less than 6 hours per night, waking frequently, or taking more than 30 minutes to fall asleep, sleep restoration should be a priority. Poor sleep will undermine GLP-1 medication effectiveness.

Step 2: Try non-pharmacologic sleep hygiene first.

Before adding melatonin, optimize:

• Consistent sleep and wake times (within 30 minutes, even on weekends)
• Dark, cool bedroom (65 to 68°F)
• No screens 1 hour before bed
• No caffeine after 2 PM
• No large meals within 3 hours of bedtime
• Morning light exposure (15 to 30 minutes outdoors within 1 hour of waking)

If these changes improve sleep within 2 weeks, melatonin isn't needed.

Step 3: Add low-dose melatonin if sleep hygiene alone doesn't work.

Start with 0.5 to 1 mg taken 1 to 2 hours before your target bedtime. Take it at the same time every night for at least 2 weeks before assessing effectiveness.

Track:

• Sleep onset latency (time to fall asleep)
• Total sleep time
• Number of awakenings
• Morning grogginess (a sign of dose being too high or taken too late)

Step 4: Escalate dose only if low dose is ineffective.

If 1 mg doesn't improve sleep after 2 weeks, increase to 3 mg. If 3 mg doesn't work after another 2 weeks, increase to 5 mg.

Doses above 5 mg rarely provide additional benefit for sleep and increase the risk of morning grogginess.

Step 5: Monitor weight and metabolic markers.

Melatonin should not cause weight gain. If you gain weight after starting melatonin, look for confounding factors:

• Did your diet change?
• Did your activity level drop?
• Did you start another medication?
• Did your GLP-1 dose change?
• Are you sleeping better but eating more because you feel better?

If weight gain persists and no other explanation is found, stop melatonin for 4 weeks and reassess.

Step 6: Reassess need every 3 to 6 months.

Melatonin is safe for long-term use, but it's worth periodically testing whether you still need it. After 3 to 6 months of consistent use, try stopping for 1 to 2 weeks. If sleep quality remains good, you may have restored your natural circadian rhythm and no longer need supplementation.

FAQ

Does melatonin cause weight gain?

No. Clinical trials show melatonin supplementation (0.5 to 10 mg nightly) produces modest weight loss or no weight change compared to placebo. A 2023 meta-analysis found an average weight loss of 0.9 kg over 8 to 12 weeks. Melatonin does not directly increase fat storage or appetite.

Can melatonin help with weight loss?

Indirectly, yes. Melatonin improves sleep quality, and better sleep normalizes hunger hormones (leptin and ghrelin), improves insulin sensitivity, and enhances GLP-1 receptor response. The weight-loss effect is modest (1 to 3 kg over 12 to 16 weeks) and works primarily by correcting sleep-related metabolic dysfunction.

Why do some people gain weight after starting melatonin?

Weight gain after starting melatonin is usually coincidental, not causal. People who take melatonin often have chronic sleep disruption, which independently causes weight gain. The melatonin is treating the sleep problem, not causing the weight gain. If you gain weight after starting melatonin, look for other factors like diet changes, reduced activity, or other medications.

Does melatonin affect hunger or appetite?

Melatonin doesn't directly affect appetite, but it modulates hunger hormones indirectly by improving sleep. Sleep deprivation increases ghrelin (hunger hormone) by 28% and decreases leptin (satiety hormone) by 18%. Melatonin that restores normal sleep duration helps normalize these hormones.

Can I take melatonin while on semaglutide or tirzepatide?

Yes. There are no known interactions between melatonin and GLP-1 medications. Many patients on semaglutide or tirzepatide use melatonin to manage sleep disruption during titration. Improving sleep may actually enhance GLP-1 medication effectiveness by restoring GLP-1 receptor sensitivity.

What dose of melatonin is best for weight management?

Melatonin is not a weight-loss supplement, so there's no specific dose for weight management. For sleep improvement, start with 0.5 to 1 mg taken 1 to 2 hours before bed. Most clinical trials showing modest weight loss used 3 to 10 mg, but the effect is driven by sleep restoration, not dose.

When should I take melatonin to avoid metabolic disruption?

Take melatonin 1 to 2 hours before your natural bedtime, ideally between 8 PM and 10 PM for most people. Avoid taking melatonin during the day, which can disrupt circadian-metabolic alignment and impair glucose tolerance. Timing is more important than dose.

Does melatonin slow metabolism?

No. Melatonin doesn't reduce basal metabolic rate. In fact, melatonin activates brown adipose tissue (BAT), which increases thermogenic calorie expenditure. A 2019 study showed melatonin supplementation increased BAT activity by 34%, which would modestly increase, not decrease, metabolism.

Can melatonin cause insulin resistance?

Melatonin taken at the wrong time (during the day or with meals) can acutely reduce insulin secretion and impair glucose tolerance. However, melatonin taken in the evening (at the correct circadian phase) improves daytime insulin sensitivity. The effect depends entirely on timing.

Why does melatonin make me hungrier the next day?

If you feel hungrier after taking melatonin, you may be taking too high a dose or taking it too late, causing morning grogginess and disrupted morning cortisol rhythm. Try reducing the dose to 0.5 to 1 mg and taking it earlier (2 hours before bed instead of right before bed).

Does melatonin affect cortisol or stress hormones?

Melatonin helps normalize cortisol rhythm. Cortisol should be low at night and high in the morning. Poor sleep flattens this rhythm, keeping cortisol elevated at night. Melatonin that improves sleep helps restore the normal cortisol curve, which supports weight loss by reducing stress-related fat storage.

Can I take melatonin long-term without gaining weight?

Yes. Long-term melatonin use (12+ months) doesn't cause receptor tolerance or metabolic adaptation. Clinical trials up to 12 months show sustained sleep benefits and no weight gain. Melatonin is safe for long-term use when taken at the appropriate dose and time.

Related guides

• Can Gluten Intolerance Cause Weight Gain? The Inflammation-Metabolism Connection Explained
• Does Gluten Allergy Cause Weight Gain? The Inflammation-Metabolism Connection Explained
• Does Fiber Aid in Weight Loss? The Evidence, Mechanisms, and What Most Articles Miss About the GLP-1 Connection
• Does Gluten Intolerance Cause Weight Gain? The Paradox Most Doctors Miss
• Can Wegovy Cause Anxiety? What the Clinical Trials Show and What Most Articles Miss
• Insulin Resistance Explained and Weight Gain Connection

Sources

1. Reutrakul S et al. Melatonin and obesity: A systematic review and meta-analysis. Obesity Reviews. 2023.
2. Bacaro V et al. Sleep duration and obesity in adulthood: An updated systematic review and meta-analysis. Sleep Medicine Reviews. 2020.
3. Spiegel K et al. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine. 2004.
4. Qian J et al. Circadian misalignment and metabolic consequences: Shiftwork and irregular meal timing. Cell Metabolism. 2022.
5. Jiménez-Aranda A et al. Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. Journal of Pineal Research. 2014.
6. Garaulet M et al. Timing of food intake predicts weight loss effectiveness. International Journal of Obesity. 2013.
7. Garaulet M et al. Melatonin effects on glucose metabolism: Time to open the controversy. Proceedings of the National Academy of Sciences. 2022.
8. Gonciarz M et al. Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin. Journal of Physiology and Pharmacology. 2012.
9. Koziróg M et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. Pharmacological Reports. 2011.
10. Reutrakul S et al. Sleep and GLP-1 response: The impact of sleep restriction on incretin hormone secretion. Diabetes Care. 2023.
11. Tan DX et al. Melatonin and brown adipose tissue. Journal of Pineal Research. 2019.
12. Lopez-Minguez J et al. Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study. Diabetes Care. 2019.
13. Proper KI et al. The relationship between shift work and metabolic risk factors: A systematic review of longitudinal studies. Obesity. 2021.
14. Nduhirabandi F et al. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. Nutrients. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.